Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Editas Medicine (NQ: EDIT )

2.910 +0.010 (+0.34%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Editas Medicine

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Expert Outlook: Editas Medicine Through The Eyes Of 7 Analysts
Via Benzinga
Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept
Webinar to be held on Tuesday, October 22, at 8:00 a.m. ET 
From Editas Medicine, Inc.
Via GlobeNewswire
Where Editas Medicine Stands With Analysts
Via Benzinga
Unveiling 5 Analyst Insights On Editas Medicine
Via Benzinga
Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust
Strengthens balance sheet with non-dilutive capital to enable further pipeline development and related strategic priorities 
From Editas Medicine, Inc.
Via GlobeNewswire
Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.
Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following patient deaths. 
Via Investor's Business Daily
Looking for Stock Bargains With Room to Run? Try This.
Investing tips from Bill Mann, The Motley Fool's director of small-cap research. 
Via The Motley Fool
Editas Medicine to Participate in Upcoming Investor Conferences
From Editas Medicine, Inc.
Via GlobeNewswire
The Analyst Verdict: Editas Medicine In The Eyes Of 4 Experts
Via Benzinga
Boot Barn To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Editas Medicine Announces Second Quarter 2024 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update
From Editas Medicine, Inc.
Via GlobeNewswire
3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition
Explore gene-editing stocks with potential to become multibaggers as the industry advances in treating genetic disorders. 
Via InvestorPlace
3 Profitable CRISPR Stocks Earning Analysts’ Praise
Revolutionary gene-editing technologies provide promise for investors seeking the most profitable CRISPR stocks today and in the future. 
Via InvestorPlace
The 3 Best Gene Editing Stocks to Buy in July 2024
Gene editing is revolutionizing medicine, creating substantial opportunities for some of the best gene editing stocks. 
Via InvestorPlace
Rags to Riches: 3 Gene Editing Stocks That Could Make Early Investors Rich
Gene editing is a game-changer, creating substantial opportunities for some of the leading gene editing stocks. 
Via InvestorPlace
3 Gene Editing Stocks That Could Make Your Grandchildren Rich
Explore gene-editing stocks with long-term growth potential, offering innovative solutions to previously untreatable conditions. 
Via InvestorPlace
Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress
From Editas Medicine, Inc.
Via GlobeNewswire
Overlooked and Undervalued: 3 Stocks With Jaw-Dropping Upside Potential
Invest in these undervalued stocks poised for long-term growth as Wall Street shifts focus to broader market gains. 
Via InvestorPlace
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
From Editas Medicine, Inc.
Via GlobeNewswire
1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5?
The company has great potential if and when it enters the commercial stage. 
Via The Motley Fool
EDIT Stock Earnings: Editas Medicine Misses EPS, Misses Revenue for Q1 2024
EDIT stock results show that Editas Medicine missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Editas Medicine Announces First Quarter 2024 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases 
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
From Editas Medicine, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.